A. Cortoos

发表

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma

A. Jakubowiak, Shaji K. Kumar, P. Mavros, 2022, The oncologist.

New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

S. Perrotta, A. Taher, A. Kattamis, 2017, American journal of hematology.

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

Sharmila Patel, J. Laubach, P. Richardson, 2022, British journal of haematology.

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

H. Goldschmidt, C. Hofmeister, P. Moreau, 2018, Blood.

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

A. Jakubowiak, Sharmila Patel, J. Laubach, 2021, Blood.

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

A. Jakubowiak, Sharmila Patel, J. Laubach, 2021, Blood.

THE HAEMOPHAGOCYTIC SYNDROME

D. Dierickx, S. Vanderschueren, A. Cortoos, 2011, Acta clinica Belgica.

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.

A. Jakubowiak, Sharmila Patel, J. Laubach, 2022, Transplantation and cellular therapy.

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

S. Perrotta, A. Taher, A. Kattamis, 2016 .

P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN

A. Jakubowiak, J. Laubach, P. Richardson, 2022, HemaSphere.

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

A. Jakubowiak, Sharmila Patel, P. Richardson, 2022, Blood Cancer Journal.

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

A. Jakubowiak, Sharmila Patel, J. Laubach, 2021, Blood.

Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.

A. Jakubowiak, Sharmila Patel, J. Laubach, 2022, Journal of Clinical Oncology.

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

A. Jakubowiak, Sharmila Patel, J. Laubach, 2022, Blood.

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

A. Jakubowiak, Sharmila Patel, J. Laubach, 2023, The Lancet. Haematology.